Top

Published in:

01-08-2021 | Thrombotic Thrombocytopenic Purpura

COVID 19 infection associated with thrombotic thrombocytopenic purpura

Authors: Gaurav Dhingra, Manideepa Maji, Saikat Mandal, Sudeep Vaniyath, Gita Negi, Uttam Kumar Nath

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2021

Abstract

Thrombotic thrombocytopenic purpura (TTP) which can cause significant mortality is a thrombotic microangiopathy due to deficiency of VWF cleaving protease ADAMTS13 and as per medical literature there are examples that TTP can be caused by COVID 19 infection. A 35 years old female after admission with right sided weakness and slurring of speech was found to be COVID positive and diagnosed as a case of TTP. Patient had absent ADAMTS13 level on day 1. Treatment was started with therapeutic plasma exchange (TPE) later injection Vincristine and Rituximab was given after 4th TPE as it was suspected as refractory case. Finally patient received 16 TPE procedures with cryo poor plasma as exchange fluid and gradually her platelet count started to maintain normal and she was discharged. Specific management and such association of this type of cases need to be studied more judiciously.

World Health Organization (2020) Director-general's remarks at the media briefing on 2019-nCoV. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Accessed 11 Nov 2020.

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H et al (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382:e38CrossRef

Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andrès E (2020) Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med 382(18):e43CrossRef

Bomhof G, Mutsaers PGNJ, Leebeek FWG, Te Boekhorst PAW, Hofland J, Croles FN, Jansen AJG (2020) COVID-19-associated immune thrombocytopenia. Br J Haematol. https://doi.org/10.1111/bjh.16850CrossRefPubMedPubMedCentral

Lopez C, Kim J, Pandey A, Huang T, DeLoughery TG (2020) Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia. Br J Haematol. https://doi.org/10.1111/bjh.16786CrossRefPubMedPubMedCentral

Hindilerden F, Yonal-Hindilerden I, Akar E, Kart-Yasar K (2020) Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: report of a case. Thromb Res 1(195):136–138CrossRef

da Silva RL (2011) Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther 4(2):51–59CrossRef

Kosugi N, Tsurutani Y, Isonishi A, Hori Y, Matsumoto M, Fujimura Y (2010) Influenza A infection triggers thrombotic thrombocytopenic purpura by producing the anti-ADAMTS13 IgG inhibitor. Intern Med 49:689–693. https://doi.org/10.2169/internalmedicine.49.2957CrossRefPubMed

Joseph A, Fangio P, Barbier C, Hayon J, Loubières Y, Pichereau C, Outin H, Alves M (2016) Seasonal flu as a triggering factor for acquired thrombotic thrombocytopenic purpura. J Hematol Thromboembolic Dis. https://doi.org/10.4172/2329-8790.1000243CrossRef

10.

Capecchi M, Mocellin C, Abbruzzese C, Mancini I, Prati D, Peyvandi F (2020) Dramatic presentation of acquired TTP associated with COVID-19. Haematologica 105(10):262345. https://doi.org/10.3324/haematol.2020.262345CrossRef

11.

Hindilerden F, Yonal-Hindilerden I, Akar E, Kart-Yasar K (2020) Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: report of a case. Thromb Res 195:136–138CrossRef

12.

Albiol N, Awol R, Martino R (2020) Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19. Ann Hematol 28:1

13.

Mancini I, Baronciani L, Artoni A et al (2021) The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost 19:513–521. https://doi.org/10.1111/jth.15191CrossRefPubMed

14.

Bazzan M, Montaruli B, Sciascia S, Cosseddu D, Norbiato C, Roccatello D (2020) Low ADAMTS 13 plasma levels are predictors of mor- tality in COVID-19 patients. Intern Emerg Med 15(5):861–863. https://doi.org/10.1007/s11739-020-02394-0CrossRefPubMed

15.

Huisman A, Beun R, Sikma M, Westerink J, Kusadasi N (2020) Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2. Int J Lab Hematol 42(5):e211–e212. https://doi.org/10.1111/ijlh.13244CrossRefPubMed

16.

COVID-19 and TTP—Hematology.org. https://www.hematology.org:443/covid-19/covid-19-and-ttp. Accessed 30 Oct 2020

17.

Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D (2005) Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution’s experience and review of the literature. Transfusion 45(1):41–49. https://doi.org/10.1111/j.1537-2995.2005.03146.xCrossRefPubMed

18.

Cheung CKM, Law MF, Lui GCY, Wong SH, Wong RSM (2019) Coronavirus disease 2019 (COVID-19): a haematologist’s perspective. Acta Haematol 2020:1–14. https://doi.org/10.1159/000510178CrossRef

Title: COVID 19 infection associated with thrombotic thrombocytopenic purpura
Authors: Gaurav Dhingra
Manideepa Maji
Saikat Mandal
Sudeep Vaniyath
Gita Negi
Uttam Kumar Nath
Publication date: 01-08-2021
Publisher: Springer US
Keywords: Thrombotic Thrombocytopenic Purpura
Rituximab
Thrombotic Microangiopathy
COVID-19
Thrombosis
Rituximab
Published in: Journal of Thrombosis and Thrombolysis / Issue 2/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-021-02452-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

COVID 19 infection associated with thrombotic thrombocytopenic purpura

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Massive pulmonary embolism in a patient with nephrotic syndrome and single lung

Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies

Nonadministration of pharmacologic venous thromboembolism prophylaxis is less common in hospitalized patients with COVID-19

Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?

Prothrombinase: the paradigm for membrane bound enzyme complexes; a memoir

Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page